Clene Inc. – NASDAQ:CLNN
Clene stock price today
Clene stock price monthly change
Clene stock price quarterly change
Clene stock price yearly change
Clene key metrics
Market Cap | 35.50M |
Enterprise value | 83.91M |
P/E | -2.35 |
EV/Sales | 177.40 |
EV/EBITDA | -3.27 |
Price/Sales | 148.88 |
Price/Book | 21.75 |
PEG ratio | 0.01 |
EPS | -0.47 |
Revenue | 620K |
EBITDA | -52.05M |
Income | -48.81M |
Revenue Q/Q | -31.77% |
Revenue Y/Y | 12.72% |
Profit margin | -6325.16% |
Oper. margin | -9420.08% |
Gross margin | 94.5% |
EBIT margin | -9420.08% |
EBITDA margin | -8396.45% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeClene stock price history
Clene stock forecast
Clene financial statements
| Jun 2023 | 269K | -25.14M | -9346.84% |
|---|---|---|---|
| Sep 2023 | 108K | -2.41M | -2238.89% |
| Dec 2023 | 170K | -10.17M | -5984.12% |
| Mar 2024 | 73K | -11.08M | -15178.08% |
| Mar 2024 | 73K | -11.08M | -15178.08% |
|---|---|---|---|
| Sep 2025 | 100K | -8.98M | -8989.6% |
| Oct 2025 | 100K | -6.42M | -6421.36% |
| Dec 2025 | 100K | -7.70M | -7705.63% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 67845000 | 46.31M | 68.26% |
|---|---|---|---|
| Sep 2023 | 60433000 | 39.02M | 64.58% |
| Dec 2023 | 52341000 | 38.95M | 74.42% |
| Mar 2024 | 45069000 | 40.80M | 90.54% |
| Jun 2023 | -7.02M | 39K | 37.83M |
|---|---|---|---|
| Sep 2023 | -6.76M | -48K | -237K |
| Dec 2023 | -7.21M | -6.21M | 35.51K |
| Mar 2024 | -7.08M | 70.99K | -19K |
Clene alternative data
| Aug 2023 | 75 |
|---|---|
| Sep 2023 | 75 |
| Oct 2023 | 75 |
| Nov 2023 | 75 |
| Dec 2023 | 75 |
| Jan 2024 | 75 |
| Feb 2024 | 75 |
| Mar 2024 | 82 |
| Apr 2024 | 82 |
| May 2024 | 82 |
| Jun 2024 | 82 |
| Jul 2024 | 82 |
Clene other data
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 250002 | 0 |
| Apr 2024 | 0 | 45500 |
| May 2024 | 0 | 13000 |
| Sep 2024 | 122819 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | MATLIN DAVID J director | Common Stock | 92,307 | $4.75 | $438,458 | ||
Purchase | MORTENSON MARK officer: Chief Sc.. | Common Stock | 20,512 | $4.75 | $97,432 | ||
Purchase | ETHERINGTON ROBERT DEE director, officer: Chief Execut.. | Common Stock | 10,000 | $4.75 | $47,500 | ||
Option | ETHERINGTON ROBERT DEE director, officer: Chief Execut.. | Common Stock | 27,320 | $3 | $81,960 | ||
Option | ETHERINGTON ROBERT DEE director, officer: Chief Execut.. | Stock Options (Right to buy) | 27,320 | $3 | $81,960 | ||
Sale | GENERAL RESONANCE LLC 10 percent owner | Common Stock | 13,000 | $0.4 | $5,148 | ||
Sale | GENERAL RESONANCE LLC 10 percent owner | Common Stock | 13,000 | $0.42 | $5,421 | ||
Sale | GENERAL RESONANCE LLC 10 percent owner | Common Stock | 10,000 | $0.33 | $3,280 | ||
Sale | GENERAL RESONANCE LLC 10 percent owner | Common Stock | 7,500 | $0.39 | $2,895 | ||
Sale | GENERAL RESONANCE LLC 10 percent owner | Common Stock | 7,500 | $0.39 | $2,903 |
| Insider | Compensation |
|---|---|
Mr. Robert Etherington MBA (1967) Chief Executive Officer, Pres & Director | $504,830 |
| Mr. Mark G. Mortenson (1958) Co-Founder & Chief Science Officer | $473,330 |
| Dr. Robert Glanzman M.D. (1957) Chief Medical Officer | $447,200 |
-
What's the price of Clene stock today?
One share of Clene stock can currently be purchased for approximately $4.41.
-
When is Clene's next earnings date?
Unfortunately, Clene's (CLNN) next earnings date is currently unknown.
-
Does Clene pay dividends?
No, Clene does not pay dividends.
-
How much money does Clene make?
Clene has a market capitalization of 35.50M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 38.27% to 654K US dollars.
-
What is Clene's stock symbol?
Clene Inc. is traded on the NASDAQ under the ticker symbol "CLNN".
-
What is Clene's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Clene?
Shares of Clene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Clene's key executives?
Clene's management team includes the following people:
- Mr. Robert Etherington MBA Chief Executive Officer, Pres & Director(age: 58, pay: $504,830)
- Mr. Mark G. Mortenson Co-Founder & Chief Science Officer(age: 67, pay: $473,330)
- Dr. Robert Glanzman M.D. Chief Medical Officer(age: 68, pay: $447,200)
-
Is Clene founder-led company?
Yes, Clene is a company led by its founder Mr. Mark G. Mortenson.
-
How many employees does Clene have?
As Jul 2024, Clene employs 82 workers.
-
When Clene went public?
Clene Inc. is publicly traded company for more then 6 years since IPO on 18 Oct 2018.
-
What is Clene's official website?
The official website for Clene is clene.com.
-
Where are Clene's headquarters?
Clene is headquartered at 6550 South Millrock Drive, Salt Lake City, UT.
-
How can i contact Clene?
Clene's mailing address is 6550 South Millrock Drive, Salt Lake City, UT and company can be reached via phone at 801 676 9695.
Clene company profile:
Clene Inc.
clene.comNASDAQ
82
Biotechnology
Healthcare
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Salt Lake City, UT 84121
CIK: 0001822791
ISIN: US1856341029
CUSIP: 185634102
